英格兰乳腺肉瘤的发病率和结局(2013-2018年):来自国家癌症注册与分析服务的分析
该研究基于英国国家癌症注册与分析服务(NCRAS)2013至2018年数据,纳入684例乳腺肉瘤患者,分析其发病与结局。中位年龄64岁,92%在诊断后12个月内接受肿瘤切除。乳腺叶状肿瘤、血管肿瘤和其他肉瘤的5年总生存率分别为82%、54%和48%,放疗相关乳腺肉瘤为55%。在专科肉瘤中心治疗的患者术前活检率更高、需多次手术的比例更低。
要点
- 684例乳腺肉瘤中,恶性叶状肿瘤357例、血管肿瘤238例、其他形态93例。
- 叶状肿瘤、血管肿瘤和其他肉瘤的5年总生存率分别为82%、54%和48%。
- 专科肉瘤中心治疗者术前活检83% vs 非专科中心72%,需多次手术26% vs 41%。
核心结论
- 这是首个评估乳腺肉瘤发病率和结局的人群系列研究。
- 在非专科肉瘤中心治疗的患者术前活检可能性更低、需多次手术的可能性更高。
- 基于这些观察性数据,作者建议所有乳腺肉瘤应在诊疗路径早期提交肉瘤多学科团队会议讨论,并尽可能考虑在专科肉瘤中心手术。
研究设计与样本
- 研究分析了国家癌症注册与分析服务(NCRAS)收集的2013至2018年诊断为乳腺肉瘤患者的数据。
- 共纳入684例患者,中位年龄64岁(范围14-96岁)。
- 使用卡方检验比较组间差异,采用Kaplan-Meier法计算总生存期(OS)。
- 专科肉瘤中心(SSC)定义为设有肉瘤多学科团队(MDT)的中心。
主要发现
- 684例患者中,恶性叶状肿瘤357例、血管肿瘤238例、其他形态93例。
- 187例(27%)曾因既往恶性肿瘤接受乳腺放疗;633例(92%)在诊断后12个月内接受肿瘤切除。
- 叶状肿瘤、血管肿瘤和其他肉瘤患者的5年OS分别为82%、54%和48%;放疗相关乳腺肉瘤患者为55%。
- 在SSC治疗的患者术前活检比例更高(83% vs 72%,p < 0.05),需多次手术的比例更低(26% vs 41%,p < 0.05)。
- 肿瘤分期和分级数据不可用。
关键数值与推荐
- 叶状肿瘤5年OS为82%,血管肿瘤为54%,其他肉瘤为48%。
- 放疗相关乳腺肉瘤5年OS为55%。
- SSC治疗者术前活检83% vs 非SSC治疗者72%(p < 0.05)。
- SSC治疗者需多次手术26% vs 非SSC治疗者41%(p < 0.05)。
临床怎么用
- 作者建议所有乳腺肉瘤应在诊疗路径早期提交肉瘤MDT会议讨论。
- 作者建议尽可能考虑在SSC进行手术。
局限性
- 肿瘤分期和分级数据不可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast sarcomas (BS) are rare cancers originating from mesenchymal breast tissue with a paucity of national population level data detailing their incidence and outcomes. METHODS: We performed an analysis of data collected by National Cancer Registration and Analysis Service (NCRAS) for patients diagnosed with BS between 2013 and 2018. Chi-square test was used to compare groups. Overall survival (OS) was calculated by Kaplan-Meier. Specialist sarcoma centres (SSC) were defined as centres with a sarcoma multidisciplinary team (MDT). RESULTS: There were 684 patients with BS (357 malignant phyllodes tumours [PTs], 238 vascular tumours, 93 other morphology) with a median age of 64 (range 14-96); 187 (27%) had received breast radiotherapy for a prior malignancy; 633 (92%) had resection of the tumour within 12 months of diagnosis. Five-year OS was 82%, 54% and 48% in patients with PT, vascular tumours and other sarcomas, respectively, and 55% for those with radiation-induced BS. Patients managed within SSC more frequently had a biopsy prior to surgery 83% versus 72%, p < 0.05) and were less likely to require multiple operations (26% versus 41%, p < 0.05). Tumour stage and grade data were not available. CONCLUSION: This is the first population series evaluating incidence and outcomes for BS. Patients treated at non-specialist sarcoma centres (NSSCs) are less likely to have a biopsy prior to surgery and more likely to require multiple operations. Based on these observational data, we would recommend all BS are discussed at a sarcoma MDT meeting early in their pathway and surgery to be considered at SSC where possible.
引用
- M A, S C, J F, et al. Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service. Eur J Cancer. 2022. PMID: 35970036. doi:10.1016/j.ejca.2022.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。